COVID-19, Lockdown Affect Trials in India But Coping Efforts In Hand
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
You may also be interested in...
Private equity-controlled Bharat Serums and Vaccines gets go-ahead in India for COVID-19-related trials with ulinastatin, an existing sepsis therapy for which it is the leading player in the country. Management also outlines how the firm is ensuring business continuity during this challenging phase.
COVID-19 and the related lockdown has sharply curtailed pharma’s face-to-face interactions with healthcare professionals. Boehringer Ingelheim India managing director Sharad Tyagi shares insights on the “extraordinary surge” in the usage of digital platforms during these challenging times. The German multinational has been able to connect with over 30,000 HCPs across the country via digital channels.
Parexel executives tell Scrip about the company’s efforts in tandem with sponsors to navigate the challenging clinical research environment amid COVID-19. A renewed interest for decentralized trials or hybrid approaches and the use of remote monitoring and telehealth visits to keep studies moving are some of the key initiatives.